Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer

Negoi, Ionut; Beuran, Mircea; Hostiuc, Sorin; El-Hussuna, Alaa; de-Madaria, Enrique

Published in:
Hepatobiliary & pancreatic diseases international : HBPD INT

DOI (link to publication from Publisher):
10.1016/j.hbpd.2019.03.011

Creative Commons License
CC BY-NC-ND 4.0

Publication date:
2019

Document Version
Accepted author manuscript, peer reviewed version

Link to publication from Aalborg University

Citation for published version (APA):
Platelet-to-lymphocyte ratio and CA 19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer

Ionut Negoi, Mircea Beuran, Sorin Hostiuc, Thomas Pinkney, Alaa El-Hussuna, Enrique de-Madaria

PII: S1499-3872(19)30072-4
DOI: https://doi.org/10.1016/j.hbpd.2019.03.011
Reference: HBPD 158

To appear in: Hepatobiliary & Pancreatic Diseases International

Received date: 18 February 2018
Accepted date: 26 March 2019

Please cite this article as: Ionut Negoi, Mircea Beuran, Sorin Hostiuc, Thomas Pinkney, Alaa El-Hussuna, Enrique de-Madaria, Platelet-to-lymphocyte ratio and CA 19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer, Hepatobiliary & Pancreatic Diseases International (2019), doi: https://doi.org/10.1016/j.hbpd.2019.03.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Editorial

Platelet-to-lymphocyte ratio and CA 19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer

Ionut Negoi\textsuperscript{1,2,*}, Mircea Beuran\textsuperscript{1,2}, Sorin Hostiuc\textsuperscript{1,3}, Thomas Pinkney\textsuperscript{4}, Alaa El-Hussuna\textsuperscript{5}, Enrique de-Madaria\textsuperscript{6}

(Negoi I, Beuran M, Hostiuc S, Pinkney T, El-Hussuna A, de-Madaria E)

\textsuperscript{1} Carol Davila University of Medicine and Pharmacy Bucharest, Romania
\textsuperscript{2} Department of General Surgery, Emergency Hospital of Bucharest, Romania
\textsuperscript{3} Department of Legal Medicine and Bioethics, National Institute of Legal Medicine Mina Minovici, Romania
\textsuperscript{4} Academic Department of Surgery, University of Birmingham, Birmingham, UK
\textsuperscript{5} Department of Surgery, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark
\textsuperscript{6} Servicio de Aparato Digestivo, Unidad de Patología Pancreática, Gastroenterology Department, Pancreatic Unit, Hospital General Universitario de Alicante, Alicante, Spain

Bucharest, Romania

* Corresponding Author: Ionut Negoi, Carol Davila University of Medicine and Pharmacy Bucharest, Romania (E-mail address: negoiionut@gmail.com)

Received: 18 February 2018
Accepted: 26 March 2019
Contributors: NI wrote the first draft of the article, performed acquisition of the data, analyzed and interpreted the data. BM analyzed and interpreted the data, revised the manuscript for important intellectual content. HS, PT, EHA and ME analyzed and interpreted the data. All authors approved the final version of the manuscript. NI is the guarantor.

Funding: None.

Ethical approval: Not needed.

Competing interest: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

We read with great interest the paper “Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer” published in Hepatobiliary & Pancreatic Diseases International [1]. The authors reviewed the oncological outcomes of 103 patients with pancreaticoduodenectomy, distal pancreatectomy or total pancreatectomy for pancreatic ductal adenocarcinoma (PDAC). They correlated the overall (OS) and disease specific survival (DSS) of these patients with platelet-to-lymphocyte ratio (PLR) and carbohydrate antigen 19-9 (CA 19-9) level which were measured within one month prior to surgery. The authors used cutoff values of 129.1 for PLR and 74.0 U/mL for CA 19-9. The worst prognosis was found for patients with high PLR and high CA 19-9 (five-year OS=11.9%, DSS=16.8%). An intermediate survival for patients with either one of the two factors was decreased (five-year OS=31.9% and DSS=36.4%), and the best prognosis for patients with low PLR and low CA 19-9 (five-year OS=44.0% and DSS=47.7%).

Incidence of pancreatic cancer is continuously increasing globally with a 33.6% increase between 1990 and 2016; 19.7% of this increase is due to the increase of aged population, 12.4% due to population growth, and 1.5% due to change in incidence rate [2]. Despite significant improvements of the surgical techniques, intensive care, adjuvant and neoadjuvant chemoradiotherapy regimen and imaging, pancreatic cancer
continues to be one of the most lethal human malignancies [3–6]. There are significant efforts in the fundamental and clinical research to find genetic and epigenetic biomarkers with increased accuracy to guide therapy in patients with PDAC [7, 8]. CA 19-9 and PLR are easily accessible, informative, and seem to correlate with prognosis in patients with surgical resection for pancreatic cancer.

CA 19-9, also termed as sialyl Lewis-a (sLea), is the most commonly used and largely studied serum tumor marker for diagnosis and post-therapy surveillance in patients with pancreatic cancer [9]. It is expressed on the surface of the cancer cells. CA 19-9 is accumulating during carcinogenesis due to epigenetic silencing of the gene for 2-6 sialyl transferase [10]. The CA 19-9 was reported to be also useful in predicting prognosis in patients with pancreatic cancer [11]. Hata et al. analyzed 269 resected patients with PDAC and revealed that lymph node metastasis (P<0.0001) and postoperative CA 19-9 > 37 U/mL (P<0.0001) were independent predictors of poor survival. Patients with higher postoperative CA 19-9 levels had a higher rate of microscopically positive resection margins, hepatic and peritoneal recurrences [12]. Postoperative CA 19-9 level seems to be a better prognostic factor than its preoperative measurement, and radical surgery should be offered irrespective of its initial value [12]. Hayasaki et al. analyzed 307 patients undergoing surgical resection after neoadjuvant chemoradiotherapy [13]. They found that DSS was significantly poorer in resectable patients with pretreatment CA 19-9 > 500 U/mL, and that CA 19-9 was not associated with DSS in resected patients with borderline resectable or locally advanced disease [13].

The inflammation represents a crossroad between intrinsic factors (genome stability genes, oncogenes, tumor suppressors) and local microenvironment (immune factors and stromal tissue) contributing to carcinogenesis and cancer progression [14–16]. Very refined prognostic biomarkers, such as IL-2, IL-6, IL-10, vascular endothelial growth factor (VEGF) and transforming growth factor (TGF), are investigated in scientific research [17, 18]. However, important information about systemic inflammation, to help decision making in daily clinical practice can be obtained from routine blood samples (PLR, neutrophil-to-lymphocyte ratio [NLR],
C-reactive protein) [1,19]. A meta-analysis of 34 studies including 7105 patients with pancreatic cancer revealed that high PLR and NLR were defined as values from 150 to 200, and 2 to 5, respectively [20]. They found a significant correlation between high PLR (HR=1.143, 95% CI: 1.037 to 1.259) and NLR (HR=1.737, 95% CI: 1.502 to 2.009) and poor survival. Both parameters had no prognostic role in patients who underwent chemoradiotherapy [20]. Song et al. conducted a meta-analysis of 8 studies including 1904 patients with pancreatic cancer [21], and found that the PLR was associated with decreased OS (HR=1.22, 95% CI: 1.04 to 1.43, P = 0.02), especially in Asian studies, patients with metastatic disease and for values of PLR over 150.

In conclusion, CA 19-9 and platelet-to-lymphocyte ratio are easily accessible, informative, and correlate with prognosis in patients with surgical resection for pancreatic cancer. However, studies investigating these biomarkers present a significant heterogeneity, and should be validated by prospectively collected data.

References


4 Negoi I, Beuran M, Hostiuc S, Negoi RI, Inoue Y. Surgical Anatomy of the


(Basel) 2018;10.


